LNSR
Held · Bookmarked
4 · 0
portfolios · users
Platform exposure
$50.9K
13F filers
1
institution
Market cap
$69.5M
12M shares
52-week range
$5.06 – $13.47
8% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.82%
Easy to borrow
Price (6 mo)
LENSAR, Inc. Common Stock
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.
www.lensar.com- Employees
- 150
- IPO / List date
- Sep 21, 2020
- HQ
- ORLANDO, FL
Held by traders on TradeandTell
| Trader / Portfolio | Shares | Value |
|---|---|---|
| Robinhood — Robinhood IndividualZulle | 350 | $2,009.00 |
| THE DEEP ENDZulle | 8,185 | $46,981.90 |
| Robinhood — Robinhood Roth IraZulle | 335 | $1,922.90 |
| Robinhood — Robinhood Individualb | 1 | $5.74 |
Super investors & insiders
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 313,645 | $4.4M |
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
People who hold LNSR also hold
GGR
Gogoro Inc. Ordinary Shares
3 co-holders · 75% overlap
DDI
DoubleDown Interactive Co., Ltd. American Depository Shares
3 co-holders · 75% overlap
GAMB
Gambling.com Group Limited Ordinary Shares
3 co-holders · 75% overlap
META
Meta Platforms, Inc. Class A Common Stock
1 co-holder · 25% overlap
BMBL
Bumble Inc. Class A Common Stock
3 co-holders · 75% overlap
GOOGL
Alphabet Inc. Class A Common Stock
1 co-holder · 25% overlap
NET
Cloudflare, Inc. Class A common stock, par value $0.001 per share
1 co-holder · 25% overlap
NNDM
Nano Dimension Ltd. American Depositary Shares
2 co-holders · 50% overlap
Ranked by collective conviction (sum of co-holders' % allocation) across public portfolios holding LNSR.
Recent trades on TradeandTell
- 6/17/2026in Robinhood — Robinhood Roth Ira →
- 6/17/2026in Robinhood — Robinhood Individual →
- 6/17/2026in Robinhood — Robinhood Individual →
- 6/17/2026
Reliable revenue, superior product in the medical equipment niche that allows for superior cataract surgery throughput and high margin procedural revenue share. Experiencing temporary sell pressure from a failed acquisition as special sit arb's fled the stock halfway through a transitionary year on their way to positive cashflow and hopefully a return to previous system sales growth as they reestablish connections overseas.
in THE DEEP END →
$LNSR chatter on StockTwits
$GAMB June 26 LOC order it is alongside $LNSR and $FTLF we'll see if it maintains these price levels leading up to the closing cross.
View on StockTwits ↗@Mike22332233 @puzzled222 Ask me about my bag of $LNSR shares. Shoutout $ALC and FTC for the failure.
View on StockTwits ↗
LENSAR Q1 Earnings Call Highlights $LNSR #LENSAR #instantalerts #NASDAQ:LNSR https://www.marketbeat.com/instant-alerts/lensar-q1-earnings-c
View on StockTwits ↗
$LNSR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.56 up 167.24% YoY • Reported revenue of $13.43M down -5.16% YoY
View on StockTwits ↗
$LNSR maybe a half double from here.. ‘Hope $5 the bottom..
View on StockTwits ↗
For $LNSR, procedure volume has been doing well, with a >21% jump y/y, now up to >23% share in the U.S. The problem is with system sales, which are lacking. Management blames international distributors for being hesitant because of the merger. Not sure I buy that.
View on StockTwits ↗
Today’s move in $LNSR feels like a mix of beta tailwinds and a hint of alpha starting to show. What stood out? Recurring revenue. That’s the piece the market actually rewards over time — more predictable, more defensible, more scalable. That’s a quiet but important signal. The bigger question: why couldn’t the machines keep building on that earlier momentum? Lantern Pharma is at a point where execution matters more than narrative. If management can reignite growth and operational consistency over the next few quarters, this could shift from “watchlist” to “story re-rating.” For now, it’s not about one day’s price action — it’s about whether this becomes sustained traction or just another chop phase.
View on StockTwits ↗$LNSR Second best sales revenue ever. Highest procedure volume ever. Things are still moving. Was $16 on 4q earnings day last year.. Risk reward at $6 pretty dang good. Long.
View on StockTwits ↗
$LNSR Lensar reports Q4 EPS (12c) vs. ($1.61) last year Reports Q4 revenue $16.03M vs. $16.73M last year. "While the recent transaction-related news was unexpected, we have quickly pivoted and are moving forward independently with a renewed commitment to advancing robotic laser cataract surgery through our industry-leading ALLY Robotic Laser Cataract System. Our objective is not only to expand our share of the laser-assisted cataract surgery market, but to expand the robotic laser cataract market itself, and continue to demonstrate we are well equipped to do so," said CEO Nick Curtis. "We closed 2025 with continued momentum in ALLY adoption and utilization, reinforcing the durability of our recurring revenue model, with 79% of revenue for both the fourth quarter and the full year coming from recurring sources. During Q4, we expanded the ALLY installed base to approximately 200 systems, representing a 48% increase over the end of 2024, while worldwide volume increased 22% in 2025 compared to 2024. Procedure growth, both in the U.S. and abroad, remained robust and reflects increasing utilization across our growing installed base, providing clear evidence of the compelling value surgeons see in our technology and a clear path for LENSAR to continue growing its recurring revenue base and its overall business."
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.